Recent Updates
Recently added Catalysts
ORIC Positive Sentiment Score: 75/100

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

Key Takeaway: ORIC Pharmaceuticals will showcase its initial Phase 1b clinical data for ORIC-114, targeted at EGFR/HER2 exon 20 mutations in non-small cell lung cancer (NSCLC) at the ESMO Congress 2023. The congress, taking place from October 20-24 in Madrid, will feature two poster presentations detailing the study results. A conference call on October 21 will include insights from Dr. Alexander Spira, highlighting the therapeutic promise of ORIC-114. Additional preclinical data on atypical mutations will also be presented.

Market Sentiment Analysis

POSITIVE FACTORS

  • ORIC Pharmaceuticals is presenting initial Phase 1b data, which indicates progress in clinical trials.
  • The ESMO Congress provides a prominent platform for showcasing ORIC-114's potential.
  • The involvement of Dr. Alexander Spira in the conference call indicates credible expert support.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present two poster presentations at the European Society of Medical Oncology (ESMO) Congress 2023 taking place October 20-24, 2023, in Madrid, Spain. The presentations will highlight the initial Phase 1b clinical data for ORIC-114 in EGFR/HER2 exon 20 mutated cancers and new preclinical data for ORIC-114 demonstrating activity against additional atypical mutations in EGFR.
In conjunction with the ESMO presentations, ORIC will host a conference call and webcast on Saturday, October 21, 2023, at 9:00 a.m. ET. Management will be joined by Dr. Alexander Spira, Clinical Director, NEXT Oncology-Virginia, who will share his perspective on the initial data from the Phase 1b study and the potential of ORIC-114 to treat EGFR/HER2 exon 20 mutated cancers.
Details of the ESMO poster presentations are as follows:
Title: A Global Phase 1b Study of ORIC-114, a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, in Patients with Advanced Solid Tumors Harboring EGFR Exon 20 or HER2 Alterations
Poster #: 1333P
Poster Session: NSCLC, metastatic
Date & Time: Monday, October 23, 2023, at 9:00 a.m. CEST
Title: Preclinical Activity of ORIC-114, a Highly Selective, Brain Penetrant,
Irreversible Kinase Inhibitor, Against Atypical Mutations in EGFR
Poster #: 1345P
Poster Session: NSCLC, metastatic
Date & Time: Monday, October 23, 2023, at 9:00 a.m. CEST
Full abstracts are available for public viewing via the ESMO website. ePosters will be available Saturday, October 21, 2023, at 9:00 a.m. CEST.
Conference Call and Webcast Details
To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of the company’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.
About ORIC Pharmaceuticals, Inc.
Dominic Piscitelli, Chief Financial Officer

Frequently Asked Questions

What will ORIC Pharmaceuticals present at ESMO 2023?

ORIC Pharmaceuticals will present two posters showcasing initial Phase 1b data for ORIC-114.

When is the conference call regarding ORIC-114 data?

The conference call is scheduled for October 21, 2023, at 9:00 a.m. ET.

What are the poster session details for ORIC-114?

Posters are scheduled for October 23, 2023, at 9:00 a.m. CEST during the NSCLC session.

How can I access the conference call and webcast?

You can pre-register online to join the call or access the webcast via ORIC's website.

Last updated: Oct 17, 2023